RESUMO
C-terminal Src kinase (Csk) is one of the critical negative regulators of the Src family of kinases. The Src family of kinases are nonreceptor tyrosine kinases that regulate inflammation, cell proliferation, motility, and adhesion. To investigate potential histologic lesions associated with systemic loss of Csk gene activity in adult mice, conditional Csk-knockout mice were examined. Cre-mediated systemic excision of Csk induced by tamoxifen treatment resulted in multiorgan inflammation. Specifically, induction of Csk gene excision with three days of tamoxifen treatment resulted in greater than 90% gene excision. Strikingly, these mice developed enteritis that ranged from minimal and suppurative to severe, fibrinonecrosuppurative and hemorrhagic. Other inflammatory lesions included suppurative pneumonia, gastritis, and myocarditis, and increased numbers of inflammatory cells within the hepatic parenchyma. When tamoxifen treatment was reduced from three days to one day in an effort to lower the level of Csk gene excision and limit lesion development, the mice developed severe suppurative to pyogranulomatous pneumonia and minimal to mild suppurative enteritis. Lesions observed secondary to Csk gene excision suggest important roles for Csk in downregulating the proinflammatory activity of the Src family of kinases and limiting neutrophil-mediated inflammation.
Assuntos
Inflamação/veterinária , Camundongos Knockout/metabolismo , Supuração/veterinária , Quinases da Família src/metabolismo , Animais , Southern Blotting , Proteína Tirosina Quinase CSK , Feminino , Expressão Gênica , Inflamação/metabolismo , Inflamação/patologia , Masculino , Supuração/metabolismo , Supuração/patologiaRESUMO
The Society of Toxicologic Pathology formed a working group in collaboration with the American Society for Veterinary Clinical Pathology to provide recommendations for the appropriate inclusion of clinical pathology evaluation in recovery arms of nonclinical toxicity studies but not on when to perform recovery studies. Evaluation of the recovery of clinical pathology findings is not required routinely but provides useful information on risk assessment in nonclinical toxicity studies and is recommended when the ability of the organ to recover is uncertain. The study design generally requires inclusion of concurrent controls to separate procedure-related changes from test article-related changes, but return of clinical pathology values toward baseline may be sufficient in some cases. Evaluation of either a select or full panel of standard hematology, coagulation, and serum and urine chemistry biomarkers can be scientifically justified. It is also acceptable to redesignate dosing phase animals to the recovery phase or vice versa to optimize data interpretation. Assessment of delayed toxicity during the recovery phase is not required but may be appropriate in development programs with unique concerns. Evaluation of the recovery of clinical pathology data for vaccine development is required and, for efficacy markers, is recommended if it furthers pharmacologic understanding.
Assuntos
Pesquisa Biomédica , Patologia Clínica , Testes de Toxicidade/normas , Animais , Pesquisa Biomédica/legislação & jurisprudência , Pesquisa Biomédica/normas , Cães , Haplorrinos , Camundongos , Patologia Clínica/legislação & jurisprudência , Patologia Clínica/normas , Ratos , Projetos de Pesquisa , Medição de RiscoRESUMO
Most published reviews of preclinical toxicological clinical pathology focus on the fundamental aspects of hematology, clinical chemistry, coagulation, and urinalysis in routine toxicology animal species, for example, rats, mice, dogs, and nonhuman primates. The objective of this continuing education course was to present and discuss contemporary examples of nonroutine applications of clinical pathology endpoints used in the drug development setting. Area experts discussed bone turnover markers of laboratory animal species, clinical pathology of pregnant and growing laboratory animals, clinical pathology of nonroutine laboratory animal species, and unique applications of the Siemens Advia(®) hematology analyzer. This article is a summary based on a presentation given at the 31st Annual Symposium of the Society of Toxicologic Pathology, during the Continuing Education Course titled "Nontraditional Applications of Clinical Pathology in Drug Discovery and Preclinical Toxicology."
Assuntos
Avaliação Pré-Clínica de Medicamentos , Patologia Clínica/métodos , Animais , Biomarcadores/sangue , Osso e Ossos/metabolismo , Cricetinae , Modelos Animais de Doenças , Cães , Determinação de Ponto Final , Cobaias , Humanos , Camundongos , Primatas , Coelhos , RatosRESUMO
There is an international shortage of veterinary clinical pathologists in the workplace. Current trainees in veterinary clinical pathology may choose to pursue careers in academe, diagnostic laboratories, government health services, biopharmaceutical companies, or private practice. Academic training programs attempt to provide trainees with an exposure to several career choices. However, due to the proprietary nature of much of the work in the biopharmaceutical industry, trainees may not be fully informed regarding the nature of work for veterinary clinical pathologists and the myriad opportunities that await employment in the biopharmaceutical industry. The goals of this report are to provide trainees in veterinary clinical pathology and other laboratory personnel with an overview of the work-life of veterinary clinical pathologists employed in the biopharmaceutical industry, and to raise the profile of this career choice for those seeking to enter the workforce. Biographical sketches, job descriptions, and motivation for 3 successful veterinary clinical pathologists employed in the biopharmaceutical industry are provided. Current and past statistics for veterinary clinical pathologists employed in the biopharmaceutical industry are reviewed. An overview of the drug development process and involvement of veterinary clinical pathologists in the areas of discovery, lead optimization, and candidate evaluation are discussed. Additional duties for veterinary clinical pathologists employed in the biopharmaceutical industry include development of biomarkers and new technologies, service as scientific resources, diagnostic support services, and laboratory management responsibilities. There are numerous opportunities available for trainees in veterinary clinical pathology to pursue employment in the biopharmaceutical industry and enjoy challenging and rewarding careers.
Assuntos
Indústria Farmacêutica , Patologia Clínica , Médicos Veterinários/tendências , Biomarcadores , Ensaios Clínicos como Assunto , Desenho de Fármacos , Indústria Farmacêutica/tendências , Drogas em Investigação , Patologia Clínica/tendências , Fatores de Tempo , Recursos HumanosRESUMO
Enzyme-linked and electrochemiluminescence immunoassays were developed for quantification of amino (N-) terminal fragments of the skeletal muscle protein titin (N-ter titin) and qualified for use in detection of urinary N-ter titin excretion. Urine from normal subjects contained a small but measurable level of N-ter titin (1.0 ± 0.4 ng/ml). A 365-fold increase (365.4 ± 65.0, P = 0.0001) in urinary N-ter titin excretion was seen in Duchene muscular dystrophy (DMD) patients. Urinary N-ter titin was also evaluated in dystrophin deficient rodent models. Mdx mice exhibited low urinary N-ter titin levels at 2 weeks of age followed by a robust and sustained elevation starting at 3 weeks of age, coincident with the development of systemic skeletal muscle damage in this model; fold elevation could not be determined because urinary N-ter titin was not detected in age-matched wild type mice. Levels of serum creatine kinase and serum skeletal muscle troponin I (TnI) were also low at 2 weeks, elevated at later time points and were significantly correlated with urinary N-ter titin excretion in mdx mice. Corticosteroid treatment of mdx mice resulted in improved exercise performance and lowering of both urinary N-ter titin and serum skeletal muscle TnI concentrations. Low urinary N-ter titin levels were detected in wild type rats (3.0 ± 0.6 ng/ml), while Dmdmdx rats exhibited a 556-fold increase (1652.5 ± 405.7 ng/ml, P = 0.002) (both at 5 months of age). These results suggest that urinary N-ter titin is present at low basal concentrations in normal urine and increases dramatically coincident with muscle damage produced by dystrophin deficiency. Urinary N-ter titin has potential as a facile, non-invasive and translational biomarker for DMD.
Assuntos
Conectina/urina , Distrofia Muscular de Duchenne/urina , Adolescente , Corticosteroides/uso terapêutico , Fatores Etários , Animais , Estudos de Casos e Controles , Criança , Pré-Escolar , Conectina/sangue , Creatina Quinase/sangue , Estudos Transversais , Humanos , Técnicas Imunoenzimáticas , Camundongos , Camundongos Endogâmicos mdx , Distrofia Muscular Animal/sangue , Distrofia Muscular Animal/tratamento farmacológico , Distrofia Muscular Animal/urina , Distrofia Muscular de Duchenne/sangue , Distrofia Muscular de Duchenne/genéticaRESUMO
N2a and P2a chickens, resistant and susceptible to Marek's disease (MD), respectively, were used to examine relationships between major histocompatibility complex (MHC)-restricted cytotoxic T lymphocytes (CTL) and natural killer (NK)-like cell activity with resistance to infection with Marek's disease virus (MDV). Ten-day-old chickens were infected with MDV and euthanatized at selected times to evaluate for NK cell and MHC-restricted cytotoxicity. The N2a MDV-infected chickens had an early cell-mediated immune response characterized by a sustained NK-like cytotoxicity that coincided with a measurable MHC-cytotoxicity that was lower than controls. Although MHC-restricted and NK cell cytotoxicity was demonstrated in P2a MDV-infected chickens at 8 dpi, both abruptly decreased and remained low for the remainder of the 20-day experiment. The critical time point that may determine the resistance to MD appears to be within the first 2 weeks post-infection. Improvement of the chicken NK cell activity may be a good candidate for both selection and immunomodulation MD control programs.
Assuntos
Galinhas/imunologia , Herpesvirus Galináceo 2/imunologia , Doença de Marek/imunologia , Animais , Citotoxicidade Imunológica/imunologia , DNA Viral/química , DNA Viral/genética , Suscetibilidade a Doenças/imunologia , Herpesvirus Galináceo 2/genética , Imunidade Celular/imunologia , Células Matadoras Naturais/imunologia , Complexo Principal de Histocompatibilidade/imunologia , Doença de Marek/patologia , Reação em Cadeia da Polimerase/veterinária , Organismos Livres de Patógenos Específicos , Baço/imunologiaRESUMO
The purpose of this paper by the Regulatory Affairs Committee (RAC) of the American Society for Veterinary Clinical Pathology (ASVCP) is to review the current regulatory guidances (eg, guidelines) and published recommendations for best practices in veterinary toxicologic clinical pathology, particularly in the pharmaceutical and biotechnology industries, and to utilize the combined experience of ASVCP RAC to provide updated recommendations. Discussion points include (1) instrumentation, validation, and sample collection, (2) routine laboratory variables, (3) cytologic laboratory variables, (4) data interpretation and reporting (including peer review, reference intervals and statistics), and (5) roles and responsibilities of clinical pathologists and laboratory personnel. Revision and improvement of current practices should be in alignment with evolving regulatory guidance documents, new technology, and expanding understanding and utility of clinical pathology. These recommendations provide a contemporary guide for the refinement of veterinary toxicologic clinical pathology best practices.
Assuntos
Biotecnologia/normas , Indústria Farmacêutica/normas , Laboratórios/normas , Pessoal de Laboratório Médico/normas , Patologia Clínica/normas , Patologia Veterinária/normas , Animais , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/veterinária , Guias de Prática Clínica como Assunto , Controle de Qualidade , Sociedades Científicas , Toxicologia , Estados UnidosRESUMO
Two immunoassays using an anti-bovine haptoglobin monoclonal antibody, Hap 1, were used to measure serum haptoglobin levels in neonatal farm-raised and bob veal calves. Bob veal calves were grouped into condemned, normal, and icteric groups based on the appearance of the carcass and viscera at postmortem examination. The competitive inhibition assay was more sensitive than the direct hemoglobin binding assay in detecting low levels of haptoglobin in all groups of calves. A significant number of bob veal calves with gross postmortem lesions other than icterus had detectable haptoglobin levels. The low levels of haptoglobin that were detected were not useful in distinguishing the relative severity of the inflammatory or degenerative process; however, the predictive values of a positive and negative test suggest haptoglobin measurement may be useful as a supplemental tool in evaluating the health status of the neonatal calf.
RESUMO
Extreme eosinophilia with disseminated eosinophilic granulomatous disease is described in a 4-year-old Arabian mare. Clinical signs included weight loss, coughing, jugular distention, and ventral edema. Cutaneous lesions were not observed. Eosinophilic inflammation was observed in cytologic specimens from the respiratory tract, body cavities, and lymph nodes. At necropsy, a 20-cm diameter intrathoracic mass was observed. Smaller nodules were present in the lymph nodes, liver, spleen, adrenal glands, pancreas, and skeletal muscle. Histologically, these masses and nodules were characterized by infiltrates of eosinophils, macrophages, and multinucleated giant cells, reactive fibroplasia; and multifocal eosinophilic coagula. Microscopically, mild eosinophilic infiltrates were observed in sections of stomach, small intestine, colon, and pleura; however, gross lesions were not observed in these tissues at necropsy. The etiology of the extreme eosinophilia and disseminated eosinophilic granulomatous disease in this horse was not determined.
RESUMO
A 4-year-old, neutered male Domestic Shorthair cat with a history of depression, anorexia, and weight loss was diagnosed with acute myelogenous leukemia (AML). The cat tested positive by both the feline immunodeficiency virus antibody test and feline leukemia virus enzyme-linked immunosorbent assay test. Results of cytochemical stains on peripheral blood and bone marrow specimens indicated acute myeloid leukemia with unusual basophilic differentiation (AML, M-2B).